AbbVie migraine treatment meets late-stage study main goal
AbbVie said its late-stage study of its preventive menstrual migraine treatment in adults met the main goal.
AbbVie said on Thursday its migraine treatment met the main goal of a late-stage study evaluating it as a preventive treatment for menstrual migraine in adults.